Biolyst › RAREUltragenyx Pharmaceutical Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 25, 2026, a projected date rather than a confirmed one. There are 10 upcoming events on record.
Cash runway is approximately 1.9 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 42 concluded trials, 64% reached completion rather than being terminated or withdrawn.
Upcoming catalysts
Date Event Type Phase
October 25, 2026 est.
Next quarterly earnings (projected) Earnings
—
January 15, 2027
Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta Trial Milestone
Phase 3
August 15, 2027
A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD Trial Milestone
Phase 3
August 15, 2027
Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA Trial Milestone
Phase 3
September 15, 2027
Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency Trial Milestone
Phase 3
December 15, 2028
First-in-human Study of UX016 in GNEM Trial Milestone
Phase 1/Phase 2
February 15, 2029
Long-term Extension of GTX-102 in Angelman Syndrome Trial Milestone
Phase 3
March 15, 2029
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH Trial Milestone
Phase 2/Phase 3
March 15, 2029
A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease Trial Milestone
Phase 1/Phase 2
January 15, 2030
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS) Trial Milestone
Phase 2
Track RARE alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open RARE in the tracker
Recent history
Date Event Type Phase
October 14, 2026
8-K filed: Material agreement Corporate
—
October 7, 2026
8-K filed: Material agreement Corporate
—
September 17, 2026
8-K filed: Other event Filing
—
September 2, 2026
8-K filed: Other event Filing
—
August 19, 2026
8-K filed: Other event Filing
—
August 11, 2026
8-K filed: Other event Filing
—
August 4, 2026
Quarterly results filed (8-K) Earnings
—
July 10, 2026
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS) Trial Milestone
Phase 3
May 18, 2026
8-K filed: Leadership change Corporate
—
May 5, 2026
Quarterly results filed (8-K) Earnings
—
April 2, 2026
8-K filed: Other event Filing
—
March 30, 2026
8-K filed: Other event Filing
—
March 12, 2026
8-K filed: Other event Filing
—
February 23, 2026
8-K filed: Other event Filing
—
February 12, 2026
Quarterly results filed (8-K) Earnings
—
February 3, 2026
8-K filed: Other event Filing
—
January 30, 2026
8-K filed: Other event Filing
—
January 12, 2026
Quarterly results filed (8-K) Earnings
—
December 30, 2025
8-K filed: Other event Filing
—
December 29, 2025
8-K filed: Other event Filing
—
November 4, 2025
Quarterly results filed (8-K) Earnings
—
October 30, 2025
8-K filed: Other event Filing
—
October 23, 2025
Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Trial Milestone
Phase 3
October 20, 2025
Setrusumab vs Placebo for Osteogenesis Imperfecta Trial Milestone
Phase 2/Phase 3
September 8, 2025
8-K filed: Other event Filing
—
August 18, 2025
8-K filed: Other event Filing
—
August 5, 2025
Quarterly results filed (8-K) Earnings
—
July 31, 2025
8-K filed: Other event Filing
—
July 11, 2025
8-K filed: Other event Filing
—
July 9, 2025
8-K filed: Other event Filing
—
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.